Grant Life Sciences, Inc. (GLIF.OB)

Grant Life Sciences, Inc., a development stage company, engages in the development of antibody-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. Its tests detect the presence of various antibodies that appear when cervical cancer or pre-cancerous conditions are present in the body by analyzing a small amount of the patient’s blood. Grant Life also holds rights to diagnostic devices for HIV-1, HIV-2, and dengue fever testing; and a proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests. The company was founded in 1998 and is based in Los Angeles, California.

For the nine months ended 30 September 2006, Grant Life Sciences, Inc. reported no revenue. Net loss fell 43% to $7.5M. Revenues reflect the Company being in the development stage. Lower loss reflects a decrease in general & administrative expenses, lower research & development expenditure, a decrease in change in fair value related to adjustment of derivative & warrant liability to fair value of underlying securities expenses.